The Board of Directors of the Shanghai Henlius Biotech, Inc. announced that the application for phase 1b/2 clinical trial for HLX208 (BRAF V600E inhibitor) ("HLX208") monotherapy or in combination therapy for the treatment of BRAF V600E or BRAF V600 mutation-positive advanced solid tumours has recently been approved by the National Medical Products Administration ("NMPA"). The Company intends to conduct clinical trials for the relevant indications of the product in China (excluding Hong Kong, Macau and Taiwan regions, the same below) when the conditions are satisfied.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.5 HKD | +0.98% | +12.55% | +18.71% |
08:55am | Shanghai Henlius Biotech's Cancer Drug Gets the Nod from US FDA | MT |
Apr. 24 | Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+18.71% | 1.13B | |
-4.66% | 87.53B | |
+1.32% | 40.42B | |
-18.95% | 29.48B | |
+57.86% | 25.43B | |
-17.81% | 11.49B | |
-43.00% | 11.3B | |
-9.14% | 11.1B | |
+5.24% | 8.75B | |
-8.42% | 7.99B |
- Stock Market
- Equities
- 2696 Stock
- News Shanghai Henlius Biotech, Inc.
- Shanghai Henlius Biotech, Inc. Announces Approval of Application for Phase 1B/2 Clinical Trials for HLX208 (Braf V600e Inhibitor) Monotherapy or in Combination Therapy for the Treatment of BRAF V600E or BRAF V600 Mutation-Positive Advanced Solid Tumours by the National Medical Products Administration